Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tadalafil

FDA-approved product (tablet, oral), marketed as Adcirca, Alyq, Chewtadzy and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tadalafil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Erectile dysfunction
  • Impotence
  • Pulmonary arterial hypertension
  • Pulmonary hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in erectile dysfunction
FDA pharmacologic class
Phosphodiesterase 5 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tadalafil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-10.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tadalafil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effect of Combination Therapy Using Li-ESWT and PDE-5 Inhibitor in Patients With Erectile Dysfunction

    NCT05043896 · start 2019-12-10

    Registered record
    Registry ID
    NCT05043896
    Conditions
    Erectile Dysfunction
    Interventions
    Li-ESWT; Tadalafil 2.5Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-12-10
    Completion
    2020-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionLi-ESWT; Tadalafil 2.5Mg Tab
    PhaseNot applicable
    Registry statusCompleted

  • Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

    NCT03785210 · start 2019-06-05

    Registered record
    Registry ID
    NCT03785210
    Conditions
    Hepatocellular Carcinoma; Hepatocellular Cancer; Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer; Liver Metastasis
    Interventions
    nivolumab; tadalafil; oral vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-06-05
    Completion
    2022-12-31
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma; Hepatocellular Cancer; Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer +1 more
    Interventionnivolumab; tadalafil; oral vancomycin
    PhasePhase 2
    Registry statusTerminated

  • Effect of Tadalafil Administration on Vasodilatation Mediated by Flow in Patients With Obesity Grade I-II

    NCT03905018 · start 2019-05-01

    Registered record
    Registry ID
    NCT03905018
    Conditions
    Obesity and Erectile Dysfuntion
    Interventions
    Tadalafil 20 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-05-01
    Completion
    2019-09-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity and Erectile Dysfuntion
    InterventionTadalafil 20 MG
    PhasePhase 3
    Registry statusUnknown

  • Tadalafil for Erectile Dysfunction in Patients With Cirrhosis

    NCT03566914 · start 2018-06-30

    Registered record
    Registry ID
    NCT03566914
    Conditions
    Cirrhosis
    Interventions
    Tadalafil 10 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-06-30
    Completion
    2019-12-28
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis
    InterventionTadalafil 10 MG; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function

    NCT03049540 · start 2017-10-25

    Registered record
    Registry ID
    NCT03049540
    Conditions
    Heart Defects, Congenital; Transposition of Great Vessels With Ventricular Inversion
    Interventions
    Tadalafil 20 MG; Placebo 20 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-10-25
    Completion
    2021-10-28
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Defects, Congenital; Transposition of Great Vessels With Ventricular Inversion
    InterventionTadalafil 20 MG; Placebo 20 MG
    PhasePhase 3
    Registry statusCompleted

  • Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

    NCT02999906 · start 2017-10

    Registered record
    Registry ID
    NCT02999906
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Oral Treprostinil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2017-10
    Completion
    2022-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionOral Treprostinil; Placebo
    PhasePhase 3
    Registry statusWithdrawn

  • Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

    NCT03238365 · start 2017-08-10

    Registered record
    Registry ID
    NCT03238365
    Conditions
    Lip, Oral Cavity and Pharynx; Larynx
    Interventions
    Nivolumab; Tadalafil; Therapeutic Conventional Surgery
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2017-08-10
    Completion
    2022-09-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLip, Oral Cavity and Pharynx; Larynx
    InterventionNivolumab; Tadalafil; Therapeutic Conventional Surgery
    PhaseEarly phase 1
    Registry statusCompleted

  • A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects

    NCT03215966 · start 2017-08-07

    Registered record
    Registry ID
    NCT03215966
    Conditions
    Healthy Subjects
    Interventions
    Macitentan / tadalafil FDC; Macitentan (Opsumit®); Tadalafil (Adcirca®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-08-07
    Completion
    2017-09-24
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionMacitentan / tadalafil FDC; Macitentan (Opsumit®); Tadalafil (Adcirca®)
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

    NCT03240939 · start 2017-03-27

    Registered record
    Registry ID
    NCT03240939
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Dutasteride 0.5 mg; Tadalafil 5 mg; YY-201
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-27
    Completion
    2017-10-10
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionDutasteride 0.5 mg; Tadalafil 5 mg; YY-201
    PhasePhase 1
    Registry statusCompleted

  • Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms

    NCT02252367 · start 2015-12

    Registered record
    Registry ID
    NCT02252367
    Conditions
    Prostatic Hyperplasia; Lower Urinary Tract Symptoms
    Interventions
    Tadalafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-12
    Completion
    2020-06
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia; Lower Urinary Tract Symptoms
    InterventionTadalafil; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study

    NCT02601989 · start 2015-11

    Registered record
    Registry ID
    NCT02601989
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Tadalafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-11
    Completion
    2019-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionTadalafil; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study to Compare the Safety and Pharmacokinetics of CKD-397

    NCT02645890 · start 2015-11

    Registered record
    Registry ID
    NCT02645890
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    CKD-397; TD+TM
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11
    Completion
    2015-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionCKD-397; TD+TM
    PhasePhase 1
    Registry statusCompleted

  • Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

    NCT02968901 · start 2015-09-01

    Registered record
    Registry ID
    NCT02968901
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    macitentan; tadalafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-09-01
    Completion
    2018-09-10
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    Interventionmacitentan; tadalafil
    PhasePhase 4
    Registry statusTerminated

  • Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin

    NCT02239484 · start 2014-03

    Registered record
    Registry ID
    NCT02239484
    Conditions
    Erectile Dysfunction; Benign Prostatic Hyperplasia
    Interventions
    Tadalafil; Tamsulosin; Tadalafil + Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03
    Completion
    2014-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction; Benign Prostatic Hyperplasia
    InterventionTadalafil; Tamsulosin; Tadalafil + Tamsulosin
    PhasePhase 1
    Registry statusCompleted

  • Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride

    NCT01942551 · start 2013-09

    Registered record
    Registry ID
    NCT01942551
    Conditions
    Benign Prostate Hyperplasia
    Interventions
    Tadalafil; Dutasteride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09
    Completion
    2013-12
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostate Hyperplasia
    InterventionTadalafil; Dutasteride
    PhasePhase 1
    Registry statusCompleted